Intellia Therapeutics Secures $400M Non-Dilutive Loan from OrbiMed — Intellia Therapeutics, Inc.

Event summary

Intellia Therapeutics secured a $400 million non-dilutive senior secured term loan facility with OrbiMed.
The facility includes an initial $75 million term loan, with up to $225 million in additional tranches tied to milestones, and an optional $100 million subject to mutual agreement.
The financing aims to support the U.S. approval and commercial launch of lonvo-z for hereditary angioedema (HAE).
Lonvo-z, based on CRISPR/Cas9 technology, has received multiple regulatory designations, including Orphan Drug and RMAT Designation by the FDA.

The big picture

This non-dilutive financing provides Intellia with greater financial flexibility as it advances toward key milestones, including the U.S. approval and commercial launch of lonvo-z. The deal underscores the growing interest in CRISPR-based therapies and the strategic importance of securing non-dilutive funding to support high-risk, high-reward biopharmaceutical development. The scale of the loan facility highlights the confidence in Intellia's pipeline and its potential to transform treatment paradigms for severe diseases.

What we're watching

Milestone Execution: Whether Intellia can achieve the specified milestones to access the additional $225 million under the loan facility.
Regulatory Approval: The timeline and success of the U.S. approval and commercial launch of lonvo-z for HAE.
Pipeline Development: The progress of nexiguran ziclumeran through multiple milestones in transthyretin amyloidosis and the creation of value through early pipeline development efforts.